Nassos Alevizopoulos

Biography

 He has gradudated with a Diploma in Biology from the University of Athens, Nassos earned a PhD in Biology from the University of Lausanne in Switzerland, where his innovative work on the signal transduction of the cell growth regulator TGFβ and the pro-inflammatory cytokine ΤNFα culminated in the first authorship of four high-impact peer-reviewed scientific publications and in the award of the 1997 Brunner Prize of Excellence (best of 181 doctorates.) Nassos then did postdoctoral research at the Novartis Institute of Biomedical Research of Basel, Switzerland. Following a year with the CRO Quintiles in Germany, Nassos was accepted to earn an MBA in Strategy & Finance at the Lausanne Business School, graduating second in his class. Nassos has worked at Novartis as Business Planning and Analysis Manager for Oncology and Transplantation (recognized as top 7 performer in Region Europe, 2004). Other career positions include CEO of Bionova Ltd. (biotechnology transfer), Chief Executive Officer of the arthritis CRO Biomedcode SA, and Chief Operating Officer at Dyonmed S.A, a medical devices company. As a Senior Vice President of Drug Development & Licensing for Regulon Inc, an American biotech company, Nassos directed a clinical team to earn an Orphan Drug designation for a liposomal cisplatin in pancreatic cancer by European Medicines Agency. He also negotiated a termsheet of US$50M for a global Lipoplatin outlicensing deal with a $6B pharmaceutical company.

Research Interest

 Pharmaceutical Sciences